Today: October 18, 2017, 4:21 am
  
Health

Novotech signs MOU with South Korea's leading medical center, the Asan Medical Center

Novotech signs MOU with South Korea's leading medical center, the Asan Medical Center
PR-Inside.com: 2017-04-20 18:51:49
SYDNEY, Australia and SEOUL, Korea - (ACN Newswire) - Asia Pacific specialist CRO Novotech announced today it has signed a Memorandum of Understanding (MOU) with South Korea's largest medical institution - The Asan Medical Center's (AMC) Clinical Trial Center. The MOU formalises Novotech's relationship with the internationally-leading medical center and its principal investigators.

Under the terms of the MOU, the AMC will provide professional and medical advice to Novotech for clinical trials conducted in AMC; including feasibility, principal investigator selection and assistance with patient recruitment. Novotech will assist in promoting the clinical research capabilities of the AMC internationally. Both parties have agreed to continue expanding the future scope of the collaboration.


Speaking for the AMC, Director of Asan Medical Center's Clinical Trial Center Dr. Young Suk Lim said "AMC has been very successful in delivering and supporting many complicated clinical trials, including early phase clinical trials. Based on the MOU, the AMC is committed to increasing and expanding its global-level of medical and technological infrastructure, and continuing to deliver quality clinical trial support."

Commenting on the MOU, Novotech CEO Dr. John Moller said "The AMC and its Clinical Trial Center is a globally renowned medical institution. We have worked closely the AMC's Clinical Trial Center on many clinical trials over our ten-year history in South Korea and we have been impressed with the quality of clinical support delivered by the Center."

"AMC's size, high quality facilities and technological infrastructure are crucial in delivering speedy patient recruitment, quality clinical trial management and robust trial data. AMC has over 2,700 beds and the volume of available patients is huge by Western standards. Other elements which contribute to South Korea being a leading destination for clinical trials include its efficient regulatory environment and its high standards of trial conduct," added Dr. Moller, "Novotech looks forward to working with the AMC and offering the benefits of South Korea as a clinical trial destination to our clients."

To hear more about the benefits of undertaking a clinical trial in South Korea with Novotech, please contact us via www.novotech-cro.com/contact-us-0

About the Asan Medical Center

Since its establishment in June, 1989, ASAN Medical Center has achieved a world-class medical reputation as it has continued to aggressively invest in R&D and clinical treatment. AMC is leading medical development in Korea with their competitive skills and cutting-edge equipment comparable to those of advanced foreign hospitals. ASAN Medical Center is the parent hospital of eight hospitals under the ASAN Foundation. www.amc.seoul.kr/asan/lang.eng.aboutAMC.introduction.sp

About Novotech

Headquartered in Sydney, Novotech is internationally recognised as the leading regional full-service contract research organisation (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia Pacific presence included running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners. For more information, please visit www.novotech-cro.com.

Please contact:

Susan Fitzpatrick-Napier

Digital Mantra Group

T: +61 2 8218 2144 / +1 650 798 5238

E: team@dmgpr.com

W: www.digitalmantragroup.com

Corporate enquiries:

Marketing & Communications Justine Lamond

T: +61 2 8569 1458

E: communications@novotech-cro.com

For RFP enquiries:

Please fill out the form available at www.novotech-cro.com/contact-us-0

Press Information
Novotech
Sydney, Australia

Susan Fitzpatrick-Napier
Digital Mantra Group
+61 2 8218 2144
email
www.novotech-cro.com


# 591 Words
Related Articles
More From The Author
More than 94,000 Buyers Visit Spring Electronics [..]
HONG KONG - (ACN Newswire) - Organised by the Hong Kong Trade Development Council (HKTDC), the 14th Hong Kong Electronics [..]
Asia's Largest Spring Electronics Fair and ICT [..]
New Startup Zone & Tech Hall Showcase Cutting-edge, Smart Products HONG KONG, Apr 13, 2017 - (ACN Newswire) - The [..]
Modern Land Maintains "B+" by Fitch Ratings, [..]
HONG KONG, Apr 13, 2017 - (ACN Newswire) - A leading real estate developer of green technological properties - Modern [..]
HKTDC Spring Lighting Fair Welcomed About 21,000 [..]
Survey Predicts Bright Future for LED, Green & Smart Lighting HONG KONG, Apr 10, 2017 - (ACN Newswire) - The [..]
Mitsubishi Corporation to Become a Part of [..]
TOKYO, Apr 7, 2017 - (JCN Newswire) - Mitsubishi Corporation (MC) is pleased to announce that it will be working through Enspire [..]
 
More From Health
“Reverse Abscopal Effect” in Rheumatoid Arthritis Using [..]
Biotech Holdings Announces Effective Induction of “Reverse Abscopal Effect” in Rheumatoid Arthritis Using Procell Activated Stem [..]
Air Optix Aqua Contacts from Alcon Keeps [..]
Alcon Laboratories’ Air Optix Aqua 6 pack contact lenses bring together two advanced technologies designed to provide long-lasting [..]
Daily Disposable Wear from Sauflon Clariti Keeps [..]
Sauflon Clariti is designed to give customers daily disposable lenses with the benefits of silicone hydrogel material and AquaGen [..]
Understanding Prescription Opioid Addiction, Riverside Clinic [..]
A recent report on ABC News says over the past decade the use of opioid-based prescription painkillers has quadrupled. Over [..]
FSIVF Announces Free Consultation for the Patients [..]
FSIVF has announced the facility of free consultation for the first time for the patients up to 31st October in [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.